CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79.75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Pediatrix Medical Group Q3 revenue slightly beats on volume and pricing

By Reuters News


Overview

  • US physician services provider's Q3 revenue slightly beat analyst expectations, rising 1.7% yr/yr

  • Q3 adjusted EBITDA beat analyst expectations

  • Company says results driven by volume and pricing ahead of expectations


Outlook

  • Pediatrix expects full-year 2026 Adjusted EBITDA between $290 mln and $300 mln


Result Drivers

  • VOLUME AND PRICING - Co said Q3 results were driven by both patient volume and pricing performing ahead of expectations, per CEO Mark S. Ordan

  • RECENT ACQUISITIONS - Co said growth in non-same unit activity was driven by recent acquisitions, partially offset by practice dispositions

  • FAVORABLE PAYOR MIX - Co said same-unit revenue from net reimbursement-related factors increased due to a favorable shift in payor mix, higher administrative fees from hospital partners and higher patient acuity, primarily in neonatology


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Slight Beat*

$501.37 mln

$498.14 mln (7 Analysts)

Q3 Net Income

$46.99 mln

Q3 Adjusted EBITDA

Beat

$85.48 mln

$80.10 mln (7 Analysts)

Q3 Income from operations

$65.21 mln

Q3 Operating Expenses

$436.16 mln

*Applies to a deviation of less than 1%; not applicable for per-share numbers.


Analyst Coverage

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the healthcare facilities & services peer group is "buy."

  • Wall Street's median 12-month price target for Pediatrix Medical Group Inc is $28.00, about 3.1% below its October 28 closing price of $28.91

  • The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 11 three months ago


Reuters Recommended Reads

  • Oct 27 - Universal Health warns of possible impact to annual results from Medicaid changes; Q3 revenue slightly beats

  • Oct 27 - Ensign Group Q3 adjusted EPS beats estimates, revenue up on higher occupancy rates

  • Oct 27 - HCA signals flat 2027 earnings as Medicaid payments drop; shares slide


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.